Genmab A (GMAB) Income from Continuing Operations (2018 - 2026)
Genmab A's (GMAB) quarterly Income from Continuing Operations came in at 106000000.0 in Q1 2026, down 143.44% YoY from 244000000.0 in Q1 2025, and down 109.23% on a QoQ basis from 1149000000.0 in Q3 2025.
Genmab A (GMAB) Income from Continuing Operations (2018 - 2026) Analysis & Trends
Genmab A (GMAB) has 6 years of Income from Continuing Operations data on file, last reported at 106000000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 143.44% year-over-year to 106000000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1818000000.0 (up 7.13% YoY) and the FY2025 annual result came in at 963000000.0, down 15.0% from the prior year.
- Income from Continuing Operations retreated to 106000000.0 in Q1 2026, from 1149000000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 1149000000.0 in Q3 2025 to a low of 106000000.0 in Q1 2026.
- A 3-year average of 467285714.29 and a median of 395000000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2025 — Income from Continuing Operations jumped 42.03% — and 2026, when it plunged 143.44%.
- Tracing GMAB's Income from Continuing Operations over 3 years: stood at 809000000.0 in 2024, then soared by 42.03% to 1149000000.0 in 2025, then sank by 109.23% to 106000000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 106000000.0 (Q1 2026), 1149000000.0 (Q3 2025), and 531000000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Genmab A | 2.05 Bn | 548.77 Mn | 1.07 Bn | 303.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 303.00 Mn |
| Mar 31, 2026 | -106.00 Mn |
| Sep 30, 2025 | 1.15 Bn |
| Jun 30, 2025 | 531.00 Mn |
| Mar 31, 2025 | 244.00 Mn |
| Sep 30, 2024 | 809.00 Mn |
| Jun 30, 2024 | 395.00 Mn |
| Mar 31, 2024 | 249.00 Mn |
| Sep 30, 2020 | 671.00 |
| Dec 31, 2019 | 699.00 |
| Sep 30, 2019 | 699.28 Mn |
| Dec 31, 2018 | 230.60 Mn |